855793-63-4

Basic information

• Product Name: Methyl 2-amino-4-methoxy-5-(phenylmethoxy)benzoate
• Synonyms: 2-Amino-5-benzyloxy-4-methoxybenzoic acid methyl ester;Methyl 2-amino-4-methoxy-5-(phenylmethoxy)benzoate;Methyl 2-amino-5-(benzyloxy)-4-methoxybenzoate
• CAS NO: 855793-63-4
• Molecular Formula: C₁₆H₁₇NO₄
• Molecular Weight: 287.31048
• Mol File: 855793-63-4.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Density: 1.205
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 2-amino-4-methoxy-5-(phenylmethoxy)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-amino-4-methoxy-5-(phenylmethoxy)benzoate(855793-63-4)
• EPA Substance Registry System: Methyl 2-amino-4-methoxy-5-(phenylmethoxy)benzoate(855793-63-4)

Safety Data

• Hazardous Substances Data: 855793-63-4(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 645-08-9 Isovanillic acid 
• 621-59-0 isovanillin 
• 4998-07-6 4,5-dimethoxy-2-nitro-benzoic acid 
• 31839-20-0 5-hydroxy-4-methoxy-2-nitrobenzoic acid 
• 215659-03-3 methyl 5-hydroxy-4-methoxy-2-nitrobenzoate 
• 164161-49-3 methyl 5-(benzyloxy)-4-methoxy-2-nitrobenzoate 

Downstream Products

• 286371-64-0 6-(benzyloxy)-7-methoxyquinazolin-4(3H)-one 
• 1006890-01-2 7-methoxy-4-pyridin-3-yl-6-(2-quinolin-2-ylethoxy)quinazoline 
• 1311509-51-9 6-(benzyloxy)-7-methoxy-3-methylquinazolin-4(3H)-one 
• 1006890-13-6 6-(benzyloxy)-7-methoxy-N,N-dimethylquinazolin-4-amine 
• 1006889-93-5 6-(benzyloxy)-7-methoxy-4-(pyridin-3-yl)quinazoline 
• 184475-35-2 gefitinib 
• 913819-12-2 6-(benzyloxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine 
• 184475-71-6 4-(3-chloro-4-fluorophenylamino)-6-hydroxy-7-methoxyquinazoline 
• 307353-95-3 4-chloro-6-hydroxy-7-methoxyquinoline-3-carbonitrile 
• 286371-64-0 C₁₆H₁₄N₂O₃ 
• 1188908-27-1 4-(3-aminophenoxy)-7-methoxyquinazolin-6-ol 
• 1188908-26-0 C₂₂H₁₉N₃O₃ 
• 1188908-25-9 1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-hydroxy-7-methoxyquinazolin-4-yloxy)phenyl)urea 
• 909912-09-0 benzyl 2-amino-5-(benzyloxy)-4-methoxybenzoic acid 

Relevant articles and documents

QUINAZOLINONE COMPOUNDS

New quinazolinone compounds are disclosed, as well as pharmaceutical compositions containing quinazolinones and methods for the treatment of diseases and conditions associated with mitochondrial dysfunction.

Novel amide analogues of quinazoline carboxylate display selective antiproliferative activity and potent EGFR inhibition

In the present study, a novel series of quinazoline derivatives is developed for cancer therapy. All the synthesised analogues were evaluated against a panel of 60 human cancer cell lines for the antiproliferative activity. Significant and selective growth inhibition of several solid tumour cell lines such as NCI-H322M, NCI-H522 (non-small cell lung cancer), IGROV1, SK-OV-3 (ovarian cancer), TK-10 (renal cancer) and MDA-MB-468 (breast cancer) was observed. Further, all the new amide analogues strongly inhibited EGFR in low nanomolar range with morpholino quinazoline 10 producing activity (IC50 = 6.12 nM) comparable to standard drugs erlotinib and gefitinib. In addition, western blot analysis depicted inhibition of phosphorylation of EGFR by compounds 10 and 11 in MDA-MB-468 cells at 10 μM. Molecular docking studies showed the strong binding interactions with the active site of the EGFR protein. The current investigation could be extremely helpful for the development of newer therapeutically useful quinazoline based molecules for cancer therapy.

2-METHYL-QUINAZOLINES

The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula(I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.